Stockscreener 앱 받기
1.715
0.88%
0.015
전일 마감가:
$1.70
열려 있는:
$1.67
하루 거래량:
2,844
Relative Volume:
0.12
시가총액:
$12.52M
수익:
-
순이익/손실:
$-33.65M
주가수익비율:
-0.3854
EPS:
-4.45
순현금흐름:
$-20.83M
1주 성능:
-4.19%
1개월 성능:
+25.18%
6개월 성능:
-27.33%
1년 성능:
-27.64%
1일 변동 폭
$1.67
$1.7123
1주일 범위
$1.6502
$1.76
52주 변동 폭
$1.15
$3.69
미네르바 뉴로사이언스 Stock (NERV) Company Profile
명칭
Minerva Neurosciences Inc
전화
617-600-7373
주소
1601 TRAPELO ROAD, WALTHAM, MA
NERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
1.71 | 12.52M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.90 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.91 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.60 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.27 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.39 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 개시 | BTIG Research | Buy |
| 2019-10-02 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-25 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-31 | 개시 | H.C. Wainwright | Buy |
| 2017-09-01 | 개시 | Citigroup | Buy |
| 2017-03-06 | 재개 | Jefferies | Buy |
| 2016-05-12 | 재개 | Jefferies | Buy |
모두보기
미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia
Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com
Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia
FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire
Minerva Neurosciences regains Nasdaq compliance - Investing.com
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences’ (NERV) Neutral Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences stock hits 52-week low at $1.7 By Investing.com - Investing.com Australia
Investor Network: Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences stock hits 52-week low at $1.7 - Investing.com
Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences: Q4 Earnings Snapshot - CTPost
Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints - TipRanks
Minerva Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Minerva Neurosciences: Q4 Earnings Snapshot -February 25, 2025 at 07:33 am EST - Marketscreener.com
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - The Manila Times
From $30M Loss to Profit: How Minerva Turned Finances Around While Navigating FDA Hurdles - StockTitan
Minerva Neurosciences, Inc. SEC 10-K Report - TradingView
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Minerva Neurosciences stock hits 52-week low at $1.86 - Investing.com India
Minerva Neurosciences Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Minerva Neurosciences Stock Hits 52-Week Low at $2.03 - MSN
미네르바 뉴로사이언스 (NERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):